Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...
Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027Salt Lake City, UT, Oct. 15, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results